| Similar Articles |
|---|
 |
The Motley Fool
February 23, 2007
Rich Smith |
Foolish Forecast: ViaCell Doing Well? The cord blood specialist is set to report its fourth-quarter and full-year 2006 numbers shortly. Investors, here is what you can expect to see.   |
The Motley Fool
November 8, 2005
Rich Smith |
ViaCell Looks Healthier The cord blood collector reports narrowing losses. Investors, take note. |
The Motley Fool
August 2, 2010
Brian Orelli |
Back in Love With Geron Investors' love / hate relationship with Geron is back in the worship phase, with the stem cells company up 17% on Friday and nearly an additional 10% or so today. |
The Motley Fool
November 30, 2004
Rich Smith |
Breaking Rules and Saving Lives Cord blood offers an ethical means of using stem cells to heal illness. While two top companies in the field are private, over the counter traded Cryo-Cell lost as much money as it collected in revenues last year. |
BusinessWeek
June 27, 2005
Arlene Weintraub |
Stem Cells To Go ViaCell's goal is to mass-produce stem cells from umbilical cord blood. |
The Motley Fool
August 2, 2006
Rich Smith |
Foolish Forecast: Anemic ViaCell The cord blood storage specialist is due to report its second quarter 2006 numbers tomorrow. Investors, take note. |
The Motley Fool
May 4, 2006
Rich Smith |
ViaCell Looking Sickly As expected, the company remains solvent by virtue of one division: its ViaCord umbilical cord blood storage unit, which provided $11.9 million of the quarter's $12.1 million in revenues. But even that good news fails to outweigh the bad news. Investors, take note. |
The Motley Fool
August 9, 2010
Jim Mueller |
3 Stocks to Play Biotech Three promising ideas for investing in this exciting area. |
The Motley Fool
December 29, 2006
Brian Lawler |
Is Threshold on the Verge of Success? Shares of Threshold Pharmaceuticals were the second-best performer on the market yesterday, up 28% as a result of positive phase 2 clinical trial results for its lead drug, glufosfamide. |
The Motley Fool
March 2, 2005
Rich Smith |
ViaCell Under the Microscope Cord blood collector makes its first earnings announcement tomorrow. Investors will likely be shining harsh lights on the company's financial statements. |
The Motley Fool
October 12, 2010
Travis Hoium |
Geron Shares Popped: What You Need to Know Geron shares jumped 10% after the company announced that its first patient has enrolled in the company's stem cell clinical trial. |
The Motley Fool
January 4, 2005
Rich Smith |
Blood for Sale Cord blood harvester ViaCell moves closer to its IPO, with pricing to be in the $7 to $9 range and will float 7.5 million shares, though still on a date "to be announced." |
Fast Company
December 2009
Elizabeth Svoboda |
Biotechs Look Overseas to Launch a Stem-Cell Revolution According to one small biotech, the best way to launch a stem-cell revolution is to do it overseas. |
The Motley Fool
May 31, 2011
Brian Orelli |
5 Biotechs With Upcoming Clinical Trial Results Investors willing to stay in these stocks a little while could see substantial gains well ahead of FDA approvals. |
The Motley Fool
December 29, 2011
Brian Orelli |
What to Look for From Keryx and Aeterna Zentaris in 2012 The future is uncertain for these pharmaceutical companies. |
The Motley Fool
March 1, 2007
Brian Lawler |
Know Your Drug Stock ABCs: Part 2 Investing in the pharmaceutical and biotechnology industries can be difficult. Here are terms investors should know to better understand how the clinical trial process involved with bringing a drug to market works. |
The Motley Fool
January 3, 2011
Brian Orelli |
Clinical Trial Results Fail to Inspire Inspire Pharma gets cut in half after a cystic fibrosis trial failure. |
The Motley Fool
November 14, 2011
Brian Orelli |
Biotech Uncertainty = Big Upside Potential Aastrom's phase 2 and phase 3 trials don't match up. |
The Motley Fool
August 13, 2007
Rich Smith |
ViaCell Sees the Light Despite rising sales at its trademark ViaCord umbilical cord blood storage service, and gross margin from this service rising in tandem, the firm's operating and net results remain mired in thick red ink. Investors, take note. |
The Motley Fool
November 9, 2004
Charly Travers |
Are Stem Cells a Rule Breaker? Does the science offer real hope or just hype? Biotech investors take on enough risk in the normal course of drug development that they do not need to worry about whether or not the underlying technology even works. |
The Motley Fool
August 31, 2007
Brian Orelli |
A Stem-Cell Primer Public funding from states could help companies doing stem cell research. Read about Geron, StemCells, Osiris Therapeutics, ViaCell and Invitrogen, companies that may profit from the increased public spending. |
The Motley Fool
January 31, 2011
Brian Orelli |
Time to Buy Into Stem Cells? New developments bring this analyst a step closer to opening his wallet. |
Pharmaceutical Executive
October 1, 2012
Ben Comer |
Stem Cells: A Promise Deferred? Ideology, politics, and a stilted political debate may be causing pharma to overlook the potential of emerging stem cell therapies in fostering a new generation of cures. |
The Motley Fool
August 27, 2007
Brian Orelli |
Repairing a Broken Heart Stem cells may be the new cure. If research continues on track, Geron expects to ask FDA to start clinical trials late next year or in early 2009. Investors, take note. |
The Motley Fool
April 3, 2006
Seth Jayson |
No Stemming the Flow of Shares Another year, another large dollop of shares to water down the juice at StemCells. This company excels at burning money, as its cash flow statements show. Invest accordingly. |
The Motley Fool
August 8, 2006
Rich Smith |
Second Opinion on ViaCell The prognosis isn't good. Is there still hope for ViaCell? Of course! Hope springs eternal. If ViaCell can just tighten its purse strings, investors may yet find a way to save blood and make money. |
Pharmaceutical Executive
November 1, 2012
Sue Barrowcliffe |
Real World Insights Commercial teams as well as patients can benefit from managed access programs, which are designed to provide access to medicines outside of the clinical and commercial setting, for patients who have no other available treatment options. |
Salon.com
July 17, 2000
Alix Christie |
The cord-blood controversy First we were supposed to eat the placenta. Now we're supposed to freeze it. |
The Motley Fool
October 2, 2007
Brian Orelli |
PerkinElmer and ViaCell: A Bloody Good Deal? PerkinElmer buys umbilical cord storage company ViaCell for $300 million. Investors, take note; the merger may be a good fit for both companies. |
The Motley Fool
April 18, 2005
Rich Smith |
U.S. Government Out for Blood Two companies await as the Institute of Medicine advocates improvements in cord blood banking. Newly public ViaCell has been plummeting along with rival Cryo-Cell, down roughly 40% over the past three months. |
The Motley Fool
April 27, 2007
Rich Smith |
Foolish Forecast: ViaCell Doing Swell? The cord blood specialist is set to release its first-quarter 2007 earnings. Investors, here is what you can expect to see. |
Chemistry World
October 2010 |
Artificial blood Synthetic alternatives to donor blood have been stuck in development for decades. Nina Notman reports on recent promising progress |
The Motley Fool
January 25, 2005
Rich Smith |
ViaCell's Costly Mistake Cord blood harvester neglects to collect the cash with an undervalued IPO. |
The Motley Fool
February 2, 2005
Rich Duprey |
Aastrom to Leap Into Trials The biotech firm advances to the next stage of clinical studies in stem cell research. Investors, take note. |
The Motley Fool
March 5, 2007
Rich Smith |
ViaCell Not Doing Well The company's biotech half continues to sap revenue from the moneymaking side. Investors, take note. |
The Motley Fool
October 14, 2005
Tim Beyers |
Baby Breaker Birth Announcements We track the week in private equity in search of investments of the future. Virxsys... Raven Biotechnologies... |
The Motley Fool
December 22, 2009
Brian Orelli |
Pfizer Swings for the Fences A long shot, but at least it's cheap. Pfizer seems to have taken a particular liking to stem cells, having established a unit to study them last year |
Bio-IT World
Dec 2005/Jan 2006
Maureen McDonough |
The Century of the Cell Like most new life science industries, the stem cell business landscape looks like a maze. There are many paths, turns, and dead-ends, but it is quite possible that there will be more than one route to the finish line. |
BusinessWeek
May 24, 2004
Arlene Weintraub |
Want To Bank Your Own Stem Cells? One Los Angeles startup believes everyone should, to be ready when regenerative therapies start hitting the market |
The Motley Fool
March 29, 2010
Brian Orelli |
Look for Companies That Strike First Head-to-head trials, whether they're run by companies or by third parties, can be scary. But the way to make big money is by selling drugs that offer superior benefits, so investors should welcome the onslaught of upcoming comparative trial data. |
HHMI Bulletin
May 2010
Sarah C.P. Williams |
Young Again Niche cells can reverse the aging of stem cells. |
The Motley Fool
May 1, 2007
Rich Smith |
The Losses Swell at ViaCell Given that ViaCell has been ramping up its sales and marketing spending for about a year, it's about time ViaCell's stock start showing some results from this "investment." |
BusinessWeek
September 23, 2010
Rob Waters |
Stem Cells That Save Big Pharma a Bundle Drugmakers hope to save big by using stem cells to test drugs for dangerous side effects long before costly human trials are needed. |
Popular Mechanics
December 16, 2008
Michael Milstein |
Bringing Stem Cells to War: Meet the Blood Pharmers Fresher blood is better than stale: It carries more oxygen and, when transfused into patients, speeds recovery. |
The Motley Fool
July 14, 2011
Rich Smith |
What's All the Fuss About Stem Cells? Stocks are up on news of Sweden's miracle meatball. Over the weekend, Swedish researchers announced the successful transplant of an artificial trachea to a patient whose own organ had been ravaged by cancer. |
Bio-IT World
August 2005
Ellen H. Julian |
Tech Expertise Singles Out Outsourcers Biopharmaceutical companies are flocking to consultants, outsourcers, and staffing firms to help with discrete clinical trial processes to gain access to advanced technologies and reduce the drain on already-scarce IT resources. |
The Motley Fool
November 28, 2007
Brian Orelli |
Stem Your Expectations of Stem-Cell Discoveries Making "stem" cells out of skin cells isn't all it's cracked up to be. The recent discovery has a long way to go before it can catch up to the research currently being done with stem cells. |
The Motley Fool
August 8, 2007
Rich Smith |
Foolish Forecast: Watch for ViaCell to Tip Its Hand Will second-quarter results from cord-blood storage specialist ViaCell meet or exceed the relatively low management expectations? And will the next quarter improve, as the company has previously predicted? |
The Motley Fool
December 29, 2005
Rich Smith |
New Year's 2016: Four Fabulous Fads Today's passing fads are tomorrow's market dominators. Investing is already more art than science, and investing for 10 years in the future -- even more so. |
Chemistry World
May 4, 2010
Lewis Brindley |
Blood type testing for a few pence 'Our technique prints a microfluidic circuit containing the three antibodies (A, B and D) directly onto paper,' says Gil Garnier, who led the research at Monash University in Melbourne. |
